INDVNasdaqPharmaceutical PreparationsFiscal year ends December 31
Indivior Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$33.87+1.42 (+4.38%)
Close on Oct 19, 2026
- Market cap
- $4.20B
- P/E (TTM)
- 12.2
- Dividend yield
- –
Share price
+$9.39 (+38.36%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Indivior Pharmaceuticals, Inc. grew revenue 13.5% to $1.33B over the twelve months to Jun 30, 2026. Operating income rose 92.2% to $421.00M, moving the operating margin from 18.7% to 31.6%. Free cash flow was -$111.00M, down 164.2% from a year earlier.
Revenue
$1.33B
+13.5% vs. a year earlier
Operating income
$421.00M
+92.2% vs. a year earlier
Free cash flow
-$111.00M
-164.2% vs. a year earlier
EPS, diluted
$2.78
+231.0% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $4.20B
- P/E ratio
- 12.2
- Price to sales
- 3.15
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -2.64%
Fundamentals
- Revenue
- $1.33B
- Net income
- $355.00M
- EPS, diluted
- $2.78
- Free cash flow
- -$111.00M
- Book value per share
- -$1.68
- Diluted shares
- 124M
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Revenue
$1.33B+13.5% YoY
Gross profit
$1.09B+13.6% YoY
Operating income
$421.00M+92.2% YoY
Net income
$355.00M+228.7% YoY
EPS, diluted
$2.78+231.0% YoY
Free cash flow
-$111.00M-164.2% YoY
Reported periodTrailing twelve months